On May 6, 2026, OKL LEG governor approved bill SB 933, effective on Nov. 1, 2026.
On Apr. 30, OKL LEG passed bill on investigational health treatments.
OKL LEG passed SB 933 to create the Right to Try for Individualized Treatments Act.
Adds new sections to OKL INS 63; OKL INS 63-3092.1 through OKL INS 63-3092.6.
Bill Provisions
Allows eligible patients with rare/terminal conditions to request experimental medical treatments tailored to their genetic profile that are not FDA-approved.
Defines who can access treatment, establishes how treatments are provided, who pays for treatments, liability protections, patient/family protections, other limits on the law.
Key Definitions in the Act
Eligible patient must meet a set of five strict criteria on scope of condition, biological profile, have doctor recommendation, and provide written informed consent.
Defines Individualized investigational treatment as drug, biologic, or device made specifically for patient based on genetic/molecular characteristics.
Examples include personalized gene therapies, antisense oligonucleotides (ASOs).
An Eligible facility is defined as medical/research institution operating under Federalwide Assurance (FWA) rules for human subject protection.
Voluntary Participation
Manufacturers not required to provide treatments; hospitals/facilities not required to offer them; insurers/government programs not required to pay for them.
Legislative History
On Feb. 3, 2026, bill was introduced in Senate; on Mar. 11, 2026, bill passed Senate.
On Mar. 11, 2026, bill was introduced in House; on Apr. 30, 2026, bill passed House.
Effectiveness
If approved by governor, this bill will become effective on Nov. 1, 2026.
May 2026 OKL LEG Governor Approval
On May 6, 2026, OKL LEG governor approved bill SB 933, effective on Nov. 1, 2026.
Regulators
OKL LEG
Entity Types
CNSM; Ins
Reference
Act, 5/6/2026; Bill, SB933, 4/30/2026; Citation: OKL INS 63;
